NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis $12.54 -0.61 (-4.64%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$12.54▼$13.0750-Day Range$1.27▼$13.6952-Week Range$0.80▼$14.26Volume2,197 shsAverage Volume33,767 shsMarket Capitalization$20.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Finch Therapeutics Group alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Finch Therapeutics Group Stock (NASDAQ:FNCH)Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Read More FNCH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FNCH Stock News HeadlinesAugust 10, 2024 | reuters.comFinch wins US jury trial against Ferring over fecal-transplant patentsApril 14, 2024 | fool.comFinch Therapeutics Group (NASDAQ: FNCH)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.March 25, 2024 | investorplace.comFNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023March 7, 2024 | investing.comFinch Therapeutics Group Inc (FNCH)February 22, 2024 | benzinga.comFinch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest ReportNovember 5, 2023 | morningstar.comFinch Therapeutics Group Inc FNCHAugust 21, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.June 9, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common StockMay 13, 2023 | msn.comHC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy RecommendationMay 12, 2023 | marketwatch.com8-K: Finch Therapeutics Group, Inc.May 10, 2023 | finanznachrichten.deFinch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 10, 2023 | finance.yahoo.comFinch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesApril 25, 2023 | finance.yahoo.comFinch Therapeutics Announces Executive Leadership TransitionsApril 22, 2023 | finanznachrichten.deFINCH THERAPEUTICS GROUP INCApril 18, 2023 | finance.yahoo.comFinch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementApril 4, 2023 | markets.businessinsider.comFinch Therapeutics Group (FNCH) Gets a Buy from H.C. WainwrightSee More Headlines Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees190Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,750,000.00 Net MarginsN/A Pretax Margin-73,098.12% Return on Equity-69.14% Return on Assets-26.92% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual Sales$110,000.00 Price / Sales183.08 Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book1.42Miscellaneous Outstanding Shares1,606,000Free Float885,000Market Cap$20.14 million OptionableNo Data Beta1.35 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Matthew P. Blischak J.D. (Age 61)President, Secretary & CEO Comp: $558.81kMr. Lance Thibault CPA (Age 58)Chief Financial Officer Comp: $168.79kMr. James S. Sigler MBA (Age 63)Executive Vice President of CMC Key CompetitorsCurisNASDAQ:CRISGritstone bioNASDAQ:GRTSChimerixNASDAQ:CMRXMilestone PharmaceuticalsNASDAQ:MISTDBV TechnologiesNASDAQ:DBVTView All CompetitorsInsidersJeffery A. SmisekSold 6,642 sharesTotal: $17,069.94 ($2.57/share)Jeffery A SmisekSold 1,470 sharesTotal: $5,350.80 ($3.64/share)View All Insider Transactions FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed this year? Finch Therapeutics Group's stock was trading at $3.61 at the start of the year. Since then, FNCH stock has increased by 247.4% and is now trading at $12.54. View the best growth stocks for 2024 here. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($3.01) earnings per share for the quarter. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group shares reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FNCH) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
